Table 5

Stratified analysis by age on the relationship between plasma lycopene, zeaxanthin, lutein, and β-crytoxanthin and prostate cancer in 65 cases and 132 controlsa

OR (all of the cases)OR (age < 60)OR (age ≥ 60)
Lycopene
 01.001.001.00
 10.64, 0.23–1.750.53, 0.13–2.180.53, 0.08–3.37
 20.29, 0.09–0.900.02, 0.01–0.371.02, 0.15–7.10
 30.17, 0.04–0.780.05, 0.005–0.510.10, 0.003–3.31
 Trend-testP = 0.0052P = 0.0015P = 0.6133
Zeaxanthin
 01.001.001.00
 10.97, 0.31–3.070.27, 0.05–1.4029.0, 1.29–652
 20.18, 0.05–0.640.02, 0.002–0.203.69, 0.37–37.0
 30.22, 0.06–0.830.09, 0.01–0.590.81, 0.08–7.82
 Trend-testP = 0.0028P = 0.0014P = 0.3957
Lutein
 01.001.001.00
 10.96, 0.29–3.140.33, 0.05–2.045.16, 0.43–62.3
 20.17, 0.05–0.590.04, 0.01–0.250.86, 0.09–8.57
 30.30, 0.09–1.030.09, 0.01–0.801.16, 0.15–9.16
 Trend-testP = 0.0064P = 0.0025P = 0.5341
β-Cryptoxanthin
 01.001.001.00
 11.66, 0.51–5.371.17, 0.34–3.968.09, 0.76–85.7
 20.82, 0.25–2.651.67, 0.49–5.631.66, 0.24–11.8
 30.31, 0.08–1.240.15, 0.02–1.382.01, 0.25–16.1
 Trend-testP = 0.0666P = 0.2724P = 0.8584
  • a ORs were adjusted for age, race, years of education, family history of prostate cancer, pack-years of smoking, alcohol consumption, and daily caloric intake.